Anne Marie Lane,
MPH
Massachusetts Eye and Ear
Investigator
Harvard Medical School
Lecturer in Ophthalmology
anne_lane2@meei.harvard.edu
For investigator inquiries only
About My Research
Anne Marie Lane is an epidemiologist and biostatistician in the Ocular Melanoma Center. She oversees the Mass. Eye and Ear Uveal Melanoma Registry, which is a resource to better understand melanoma risk, identify biomarkers of melanoma incidence and progression, and evaluate outcomes after treatment. The ultimate goal of this research is to develop treatment strategies that will conserve visual function and improve patient survival.
Education
1979: AB, Anthropology, Harvard College
Postgraduate Training
1991: MPH, Epidemiology, Yale University School of Medicine
Academic Appointments
2014-present: Lecturer on Ophthalmology, Harvard Medical School
2005-2014: Instructor in Ophthalmology, Harvard Medical School
2004-2005: Research Associate in Ophthalmology, Harvard Medical School
Professional Memberships
Association for Research in Vision and Ophthalmology (ARVO)
Publications powered by Harvard Catalyst Profiles
- Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma. JCO Precis Oncol. 2024 Jan; 8:e2300368.
- Outcomes after Proton Beam Irradiation in Patients with Choroidal Melanoma Eligible for Investigational AU-011 Treatment. Ocul Oncol Pathol. 2023 Dec; 9(5-6):152-157.
- Survival of patients with recurrent uveal melanoma after treatment with radiation therapy. Br J Ophthalmol. 2023 Jul 03.
- Growth rate of indeterminate choroidal lesions prior to melanoma diagnosis. Graefes Arch Clin Exp Ophthalmol. 2023 Dec; 261(12):3635-3641.
- A Comparison of Treatment Outcomes after Standard Dose (70 Gy) versus Reduced Dose (50 Gy) Proton Radiation in Patients with Uveal Melanoma. Ophthalmol Retina. 2022 11; 6(11):1089-1097.
- Conservative management of suspicious melanocytic lesions of the iris. Graefes Arch Clin Exp Ophthalmol. 2019 Jun; 257(6):1319-1324.
- Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst. 2018 12 01; 110(12):1328-1341.
- Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. JAMA Ophthalmol. 2018 09 01; 136(9):981-986.
- Evaluation of choroidal lesions with swept-source optical coherence tomography. Br J Ophthalmol. 2019 01; 103(1):88-93.
- Genetic Risk Factors for Radiation Vasculopathy. Invest Ophthalmol Vis Sci. 2018 03 01; 59(3):1547-1553.
- Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas. JAMA Ophthalmol. 2017 11 01; 135(11):1191-1196.
- Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017; 12(6):e0178189.
- Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma. Trans Am Ophthalmol Soc. 2016 Aug; 114:T2.
- Long-term Risk of Melanoma-Related Mortality After Uveal Melanoma--Reply. JAMA Ophthalmol. 2016 Feb; 134(2):239-40.
- Retinal detachments after Boston Keratoprosthesis: incidence, predisposing factors, and visual outcomes. Digit J Ophthalmol. 2015; 21(4):1-15.
- Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Fovea. Ophthalmology. 2016 Feb; 123(2):369-377.
- Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol. 2015 Aug; 133(8):881-7.
- Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy. JAMA Ophthalmol. 2015 Jul; 133(7):792-6.
- Outcomes of proton therapy for the treatment of uveal metastases. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1044-50.
- Author reply: To PMID 23972322. Ophthalmology. 2014 Aug; 121(8):e39.
- A broadly applicable surgical teaching method: evaluation of a stepwise introduction to cataract surgery. J Surg Educ. 2014 Mar-Apr; 71(2):169-75.
- CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology. 2013 Nov; 120(11):2317-23.
- Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012; 7(4):e35295.
- Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol. 2011 Sep; 129(9):1127-30.
- Posterior uveal melanoma in young patients treated with proton beam therapy. Retina. 2010 Sep; 30(8):1267-71.
- Mortality after diagnosis of small melanocytic lesions of the choroid. Arch Ophthalmol. 2010 Aug; 128(8):996-1000.
- Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010 Jul; 128(7):871-5.
- Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011 Mar 01; 79(3):842-6.
- Natural history of radiation papillopathy after proton beam irradiation of parapapillary melanoma. Ophthalmology. 2010 Aug; 117(8):1617-22.
- Evaluation of the virtual mentor cataract training program. Ophthalmology. 2010 Feb; 117(2):253-8.
- Proton beam irradiation using a light-field technique for the treatment of choroidal hemangiomas. Ophthalmologica. 2010; 224(4):209-16.
- Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009 Nov; 116(11):2206-12.
- Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration. Mol Vis. 2008 Aug 11; 14:1487-95.
- Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology. 2006 Nov; 113(11):2012-9.
- Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol. 2006 Jul; 124(7):957-66.
- Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006 Jun; 47(6):2623-31.
- Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1018-22.
- Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci. 2006 Jan; 47(1):357-63.
- Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol. 2005 Apr; 123(4):509-16.
- Treatment of metastatic tumors of the choroid with proton beam irradiation. Ophthalmology. 2005 Feb; 112(2):337-43.
- Extremely discordant sib-pair study design to determine risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 2004 Apr; 122(4):575-80.
- Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002 Dec; 120(12):1665-71.
- Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002; 100:43-8; discussion 48-9.
- Photodynamic therapy: the nurse's role. Insight. 2001 Apr; 26(2):44-8.
- A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000 Jun; 118(6):773-8.
- A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol. 2000 Mar; 118(3):327-36.
- Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep; 117(9):1161-73.
- Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep; 117(9):1177-87.
- Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999 Aug; 106(8):1571-7; discussion 1577-8.
- Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol. 1998 May; 236(5):365-74.
- An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res. 1997 Jun; 7(3):237-42.
- Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995 Apr; 102(4):640-6.
- A comparison of elderly participants in a community survey with nonparticipants. Public Health Rep. 1990 Nov-Dec; 105(6):617-22.
Show More
Show Less
